← All trials
NCT01287221
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2011
- Primary completion
- Nov 1, 2012
- Completion date
- Jan 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- University of MichiganOverall official - principal investigator
- Mayo ClinicSponsor investigator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Vanderbilt UniversityCollaborator
- Rare Disease Research Network Autonomic ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.